Long-term outcome data from equine tendon regenerative medicine trials is establishing the welfare evidence base for clinical recommendations on stem cell and PRP therapy use.
The accumulation of long-term outcome data for equine tendon regenerative medicine is providing the evidence needed to make informed welfare decisions about who benefits most from these treatments. Welfare considerations extend beyond re-injury prevention to include the experience of the treatment process itself, including the bone marrow or fat harvest procedure, and the rehabilitation period. For individual horses, the welfare cost-benefit calculation depends on their specific injury characteristics, intended use, and the quality of available rehabilitation support. The development of standardized outcome reporting in equine regenerative medicine research is enabling meaningful comparison between treatments and guiding the refinement of protocols toward optimal welfare outcomes.